Physician profile
Janis E Freeman
NPI 1730493214
$2,002.57
in general payments reported to CMS, 2019-2025
15 companies · $545 in 2025
The $545 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $54.17 · 2023: $656 · 2024: $747 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,948.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $448.37 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $318.84 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $313.55 | 2023-2025 | |
| Glaxosmithkline, LLC. | $153.12 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $149.15 | 2023-2025 | |
| Lundbeck LLC | $134.78 | 2023-2025 | Rexulti |
| Ani Pharmaceuticals, INC. | $121.61 | 2023 | Purified Cortrophin Gel |
| Sumitomo Pharma America, INC. | $76.63 | 2023-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $69.66 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $62.36 | 2024-2025 | Zepbound, Mounjaro |
| Idorsia Pharmaceuticals US INC | $60.41 | 2023 | Quviviq |
| Exact Sciences Corporation | $25.46 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.46 | 2024 | Jardiance |
| Amgen INC. | $22.33 | 2025 | Otezla, Repatha |
| Shield Therapeutics INC | $20.84 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janis Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.